Adaptive Biotechnologies raises 2026 MRD revenue guide to $276M-$286M as it targets $1,700-$1,800 ASP

Earnings Call Insights: Adaptive Biotechnologies (ADPT) Q3 2026

Management View

• “Q3 was a breakthrough quarter for Adaptive. We achieved profitability at the total company level ahead of expectations, while continuing to deliver rapid MRD growth.” (CEO Chad Robins)

• “MRD revenue, excluding

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.